- call +1-201-465-4211
- email sales@mrinsights.biz
Cancer could be defined as uncontrolled cell growth in the body leading to organ malfunction. If untreated, it can lead to death. Uncontrolled growth of cell is managed by the body in several ways, one of them is by deploying white blood cells to detect and eradicate these cancerous cells. It has been discovered that the immune system could be manipulated to influence cancerous cells to destroy itself.
Scope of the Report:
This report studies the Cancer Gene Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Gene Therapy market by product type and applications/end industries.
Several unmet medical needs for treatment of cancer have encouraged R&D of cancer gene therapy. Various factors, such as increasing prevalence of cancer, rising government initiatives, increasing funding from various government and non-government organizations, are driving the global cancer gene therapy market. In addition, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment are restraining the growth of global market for cancer gene therapy.
Americas will the major revenue contributor to this market due to the huge investment in the R&D activities for the healthcare segment to curb the rising number of cancer-related deaths in the region. The region’s focus on R&D has resulted in the emergence of several new treatment options that have long-term effect with minimum side effects.
The global Cancer Gene Therapy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Gene Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Adaptimmune
Bluebird bio
Celgene
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
Altor BioScience
Amgen
Argenx
BioCancell
GlaxoSmithKline
Merck
OncoGenex Pharmaceuticals
Transgene
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Oncolytic Virotherapy
Gene Transfer
Gene-Induced Immunotherapy
Market Segment by Applications, can be divided into
Hospitals
Diagnostics Centers
Research Institutes
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Cancer Gene Therapy Market Overview
1.1 Product Overview and Scope of Cancer Gene Therapy
1.2 Classification of Cancer Gene Therapy by Types
1.2.1 Global Cancer Gene Therapy Revenue Comparison by Types (2017-2023)
1.2.2 Global Cancer Gene Therapy Revenue Market Share by Types in 2017
1.2.3 Oncolytic Virotherapy
1.2.4 Gene Transfer
1.2.5 Gene-Induced Immunotherapy
1.3 Global Cancer Gene Therapy Market by Application
1.3.1 Global Cancer Gene Therapy Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Diagnostics Centers
1.3.4 Research Institutes
1.4 Global Cancer Gene Therapy Market by Regions
1.4.1 Global Cancer Gene Therapy Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Cancer Gene Therapy Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Cancer Gene Therapy Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cancer Gene Therapy Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Cancer Gene Therapy Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cancer Gene Therapy Status and Prospect (2013-2023)
1.5 Global Market Size of Cancer Gene Therapy (2013-2023)
2 Manufacturers Profiles
2.1 Adaptimmune
2.1.1 Business Overview
2.1.2 Cancer Gene Therapy Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Adaptimmune Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bluebird bio
2.2.1 Business Overview
2.2.2 Cancer Gene Therapy Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bluebird bio Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.3 Celgene
2.3.1 Business Overview
2.3.2 Cancer Gene Therapy Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Celgene Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.4 Shanghai Sunway Biotech
2.4.1 Business Overview
2.4.2 Cancer Gene Therapy Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Shanghai Sunway Biotech Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.5 Shenzhen SiBiono GeneTech
2.5.1 Business Overview
2.5.2 Cancer Gene Therapy Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Shenzhen SiBiono GeneTech Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.6 SynerGene Therapeutics
2.6.1 Business Overview
2.6.2 Cancer Gene Therapy Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 SynerGene Therapeutics Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.7 Altor BioScience
2.7.1 Business Overview
2.7.2 Cancer Gene Therapy Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Altor BioScience Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.8 Amgen
2.8.1 Business Overview
2.8.2 Cancer Gene Therapy Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Amgen Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.9 Argenx
2.9.1 Business Overview
2.9.2 Cancer Gene Therapy Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Argenx Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.10 BioCancell
2.10.1 Business Overview
2.10.2 Cancer Gene Therapy Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 BioCancell Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.11 GlaxoSmithKline
2.11.1 Business Overview
2.11.2 Cancer Gene Therapy Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 GlaxoSmithKline Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.12 Merck
2.12.1 Business Overview
2.12.2 Cancer Gene Therapy Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Merck Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.13 OncoGenex Pharmaceuticals
2.13.1 Business Overview
2.13.2 Cancer Gene Therapy Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 OncoGenex Pharmaceuticals Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.14 Transgene
2.14.1 Business Overview
2.14.2 Cancer Gene Therapy Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Transgene Cancer Gene Therapy Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cancer Gene Therapy Market Competition, by Players
3.1 Global Cancer Gene Therapy Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Cancer Gene Therapy Players Market Share
3.2.2 Top 10 Cancer Gene Therapy Players Market Share
3.3 Market Competition Trend
4 Global Cancer Gene Therapy Market Size by Regions
4.1 Global Cancer Gene Therapy Revenue and Market Share by Regions
4.2 North America Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
4.3 Europe Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
4.5 South America Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
5 North America Cancer Gene Therapy Revenue by Countries
5.1 North America Cancer Gene Therapy Revenue by Countries (2013-2018)
5.2 USA Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
5.3 Canada Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
5.4 Mexico Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
6 Europe Cancer Gene Therapy Revenue by Countries
6.1 Europe Cancer Gene Therapy Revenue by Countries (2013-2018)
6.2 Germany Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
6.3 UK Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
6.4 France Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
6.5 Russia Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
6.6 Italy Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Cancer Gene Therapy Revenue by Countries
7.1 Asia-Pacific Cancer Gene Therapy Revenue by Countries (2013-2018)
7.2 China Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
7.3 Japan Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
7.4 Korea Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
7.5 India Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
8 South America Cancer Gene Therapy Revenue by Countries
8.1 South America Cancer Gene Therapy Revenue by Countries (2013-2018)
8.2 Brazil Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
8.3 Argentina Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
8.4 Colombia Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Cancer Gene Therapy by Countries
9.1 Middle East and Africa Cancer Gene Therapy Revenue by Countries (2013-2018)
9.2 Saudi Arabia Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
9.3 UAE Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
9.4 Egypt Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
9.5 Nigeria Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
9.6 South Africa Cancer Gene Therapy Revenue and Growth Rate (2013-2018)
10 Global Cancer Gene Therapy Market Segment by Type
10.1 Global Cancer Gene Therapy Revenue and Market Share by Type (2013-2018)
10.2 Global Cancer Gene Therapy Market Forecast by Type (2018-2023)
10.3 Oncolytic Virotherapy Revenue Growth Rate (2013-2023)
10.4 Gene Transfer Revenue Growth Rate (2013-2023)
10.5 Gene-Induced Immunotherapy Revenue Growth Rate (2013-2023)
11 Global Cancer Gene Therapy Market Segment by Application
11.1 Global Cancer Gene Therapy Revenue Market Share by Application (2013-2018)
11.2 Cancer Gene Therapy Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Diagnostics Centers Revenue Growth (2013-2018)
11.5 Research Institutes Revenue Growth (2013-2018)
12 Global Cancer Gene Therapy Market Size Forecast (2018-2023)
12.1 Global Cancer Gene Therapy Market Size Forecast (2018-2023)
12.2 Global Cancer Gene Therapy Market Forecast by Regions (2018-2023)
12.3 North America Cancer Gene Therapy Revenue Market Forecast (2018-2023)
12.4 Europe Cancer Gene Therapy Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Cancer Gene Therapy Revenue Market Forecast (2018-2023)
12.6 South America Cancer Gene Therapy Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Cancer Gene Therapy Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Cancer Gene Therapy Picture
Table Product Specifications of Cancer Gene Therapy
Table Global Cancer Gene Therapy and Revenue (Million USD) Market Split by Product Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
